Navigation Links
Study Upholds Stopping Plavix Use Before Surgery
Date:11/10/2008

Taken less than 5 days before operation leads to more bleeding, longer hospital stay, study finds

MONDAY, Nov. 10 (HealthDay News) -- Someone who has taken the clot-preventing drug Plavix less than five days before having bypass surgery runs a higher risk of excess bleeding, is more likely to require a second operation, and will spend more time in the hospital, says a study that buttresses current guidelines.

Those guidelines from the American College of Surgeons recommend discontinuing Plavix five to seven days before coronary artery bypass surgery, said Dr. Richard C. Becker, a professor of medicine in cardiology and hematology at Duke University, and co-author of a report in the Nov. 18 issue of the Journal of the American College of Cardiology.

"Those guidelines were based on data we thought could be strengthened specifically by defining what the risk of bleeding might be," Becker said. The guidelines say that bypass surgery can be done on people who have been taking Plavix, if the need for surgery is urgent, and the risk of extra bleeding is deemed acceptable.

So, Becker and his colleagues at Duke and other institutions studied 596 people who had bypass surgery at 14 hospitals for acute coronary syndromes such as heart attacks.

Major bleeding occurred in 35 percent of the 298 participants who had taken Plavix within five days of the surgery, compared to 26 percent of the 298 who had not taken the drug in that period, the researchers found.

Those who had taken Plavix were three times more likely to require a second procedure because of bleeding than those not taking the drug -- 6.4 percent versus 1.7 percent. And the average hospital stay was 9.7 days for those who took the clot-preventing medication versus 8.6 days for those who didn't.

"Those results are consistent with some prior observations," Becker said. "They added information about bleeding not only in terms of transfusions but also hospital stay and chest tube output."

Chest tube output is bleeding through the tube inserted for the bypass procedure.

The new study "is able to show that the five-day window is important," Becker said. "Every day you wait lessens the risk."

"The study has confirmed what we all suspected," said Dr. Jawahar L. Mehta, director of molecular cardiology and holder of the Stebbins Chair in Cardiology at the University of Arkansas for Medical Sciences. "I don't think there is anything in it that is upsetting. This was expected."

The risks of operating within the five-day period "have never been studied before in a systematic fashion," Mehta said.

Bypass surgery should not be performed until five days after Plavix is stopped, "unless there is an absolute emergency to operate, which is not often these days, because we have other approaches," Mehta said.

More information

Learn about the benefits and risks of taking clopidogrel from the U.S. National Library of Medicine.



SOURCES: Richard C. Becker, professor, medicine, Duke University, Durham, N.C.; Jawahar L. Mehta, director, molecular cardiology, University of Arkansas for Medical Sciences, Little Rock; Nov. 18, 2008, Journal of the American College of Cardiology


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Cornell researchers study showing evidence of a major environmental trigger for autism
2. Study confirms increased heart attack deaths in NYC ambulance diversions
3. Study improves recovery for mothers with depression
4. Companies Pay a High Price for Employees With Crohns Disease and Ulcerative Colitis, According to Study From Thomson Reuters
5. Study Finds Rise in Rate of Diagnostic Imaging in Managed Care
6. Study finds rise in rate of diagnostic imaging in managed care
7. Overnight Dialysis Saves Lives: Study
8. Superbugs on the rise in Canadian hospitals, new Queens study shows
9. First Study of War-Related Mental Disorders Among Iraqis 10 Years Post-Gulf War Published by Researchers at Wayne State University and Basrah University, Iraq
10. University of Minnesota Study Says Students Eat More Whole Grains When Gradually Added to School Foods
11. Childrens Hospital study demonstrates how bone marrow transplant can cure sickle cell disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Upholds Stopping Plavix Use Before Surgery
(Date:8/17/2017)... ... August 17, 2017 , ... When Amy Cowperthwait left the emergency ... with her a dream to make nursing education more relevant and prepare aspiring nurses ... were integrated into healthcare provider education. , “The human element was missing. ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... for a period of three years for its residential drug and alcohol detox ... given to an organization and shows the organization’s substantial conformance to the CARF ...
(Date:8/17/2017)... ... August 17, 2017 , ... The line-up includes voices ... and effectively grow a dental practice in a competitive market environment where Corporate Dentistry ... that could just transform you and your practice.” says Daniel A. ‘Danny’ Bobrow, AIM ...
(Date:8/17/2017)... ... , ... Elemental LED, a leading U.S. based engineering and technology ... products were honored with Architectural SSL Product Innovation Awards (PIA) for the ... division, Diode LED, provides a wide variety of superior quality linear, task, and accent ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... herself once more by being among Houston’s first plastic surgeons to offer boutique ... plastic surgery care without disrupting busy schedules and maintaining the utmost discretion in ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO), is ... residents. Naloxone is available without ... retail pharmacy, G-3320 Beecher Road. ... Drug Administration, is intended to block or reverse the ... loss of consciousness. The medication is often carried by ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million and ... operations Second-quarter 2017 Branded ... Second-quarter 2017 Sterile Injectables ... Second-quarter 2017 adjusted diluted earnings per ... $0.93 Second-quarter 2017 reported ...
Breaking Medicine Technology: